Overview

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
Assess the efficacy and safety of Triptorelin pamoate 3M formulation (11.25mg) when administered by subcutaneous route.
Phase:
Phase 3
Details
Lead Sponsor:
Ipsen
Treatments:
Triptorelin Pamoate